IIIB Non-small Cell Lung Research Articles

Phase III study of surgery (S) versus definitive concurrent chemoradiotherapy boost (def ccCRTx-BOx) in patients (pts) with operable (OP+) stage IIIA(N2)/selected IIIb (sel IIIB) non-small cell lung cancer (NSCLC) following induction (IND) chemotherapy (CTx) and concurrent CRTx (ESPATUE).

7510 Background: Def ccCRTx or ccCRTx + S are accepted therapies (Tx) for OP+ stage IIIA(N2) NSCLC (Albain 2009). Our multicenter phase-II showed efficacy of CTx + ccCRTx + S in IIIA(N2) / sel IIIB...

Randomized phase II study of vandetanib (V), docetaxel (D), and carboplatin (C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, or recurrent non-small cell lung cancer (NSCLC): PrECOG PrE0501—Update on maintenance treatment, progression-free survival (PFS), and overall survival (OS).

7560 Background: We tested if V, a dual inhibitor of VEGFR and EGFR, could improve PFS in patients (PTS) with NSCLC when given as induction therapy (INRx) with D and C, followed by maintenance V or P. We report updated PFS, OS, and toxicity. Methods: PTS with advanced stage NSCLC were randomized to INRx D (75 mg/m2) + C (AUC 6) on day 1 of a 21-day cycle and daily V (100 mg/day po) for 4 cycles, followed by daily V (300 mg/day po) or P until progression. We designed the study to show an improvement in PFS with the addition of V maintenance to a median of 6.2 months (mos), compared to 4.5 mos for D+C alone. Eligible PTS had measurable disease, ECOG PS 0/1, no prior cytotoxic or targeted agents for advanced disease. PTS with uncontrolled hypertension or history of QT prolongation were ineligible. Results: 162 PTS were randomized from May 2008 to Nov. 2009; 158 began INRx. 91% had Stage IV/recurrent disease; 52% were male. Median age was 63 (36-82). 58 PTS began maintenance V/P (median 3.5 cycles). 4 PTS rem...

291 Preoperative chemo-radiotherapy (CT-RT) using concurrent boost radiation (RT) and resection for good responders in stage IIIB (T4 or N3) non-small cell lung cancer (NSCLC): A feasibility study

291 Preoperative chemo-radiotherapy (CT-RT) using concurrent boost radiation (RT) and resection for good responders in stage IIIB (T4 or N3) non-small cell lung cancer (NSCLC): A feasibility study

Prognostic significance of peritumoural blood and lymphatic vessel invasion by tumour cells in T4 non-small cell lung cancer following induction therapy

We investigated the impact of new biological prognostic factors is in 28 patients receiving a median of two courses of cisplatin-based chemotherapy with (n = 14) or without (n = 14) radiation and operation for stage IIIB (T4) non-small cell lung cancer (NSCLC). After induction therapy, 5 patients had a complete and 21 a partial response; 2 had a stable disease. A complete resection was made in 26 patients (93%). Five patients (18%) had their primary tumour and involved vestiges completely sterilized. In the remaining 23, the majority of the tumours showed abnormalities in the p53 gene expression (56%), harboured proliferating cells (91%) and induced angiogenesis (91%). Peritumoural blood and lymphatic vessel invasion (PBLVI) by tumour emboli was observed in 6 tumours. With a median follow-up of 25 months, overall 3-year survival was 48%; disease-free survival (DFS) has not been reached yet. The only significant factor influencing DFS in multivariate analysis was PBLVI by tumour cells; PBLVI-positive patients had a significantly higher likelihood ratio (P = 0.000001) of developing metastasis than their PBLVI-negative counterparts. This study documents the prognostic implication of PBLVI by tumour cells in T4 NSCLC.